Introduction
There have been several reports of neutropenia in patients taking cimetidine (Ufberg et al., 1977; Klotz and Kay, 1978) In view of the possibility of cimetidine-induced agranulocytosis the drug was discontinued on 28 July. Following this there was a gradual recovery in the peripheral blood neutrophil count (Fig. 1) (1977) .
It is interesting that the agranulocytosis developed in the context of hepatic decompensation since in a series of patients in fulminant hepatic failure treated with cimetidine no instances of neutropenia were noted (MacDougall and Williams, 1978) . The urinary excretion of cimetidine following oral administration is variable and has been noted to be as low as 60% in some cases (Burland et aL, 1975) . It is therefore possible that individual patients with hepatic failure may demonstrate high blood levels of the drug. Indeed, Dupont et al., (1981) found that a group of patients with cirrhosis treated with 1200 mg/day cimetidine for gastro-intestinal bleeding (a dose similar to that administered to the patient described here) showed significantly higher plasma cimetidine levels than a group of non-cirrhotic patients treated with a similar regime. They advised a dosage of 200-400 mg/day of cimetidine in cirrhotic patients suffering from gastro-intestinal haemorrhage. Sonne et al. (1981) reported a normal clearance of cimetidine in patients with compensated cirrhosis but these cases were only treated with 200 mg cimetidine/day and were not bleeding at the time of the study.
It is also possible that the multiple medical problems, including hepatic dysfunction, in this deteriorating patient may have led to a condition of enhanced granulopoietic susceptibility to cimetidine as has been suggested by Freston (1979) .
Further investigation is required into levels of plasma cimetidine in patients with hepatic failure on different doses of cimetidine. 
